Table 3.

Comparison of the different criteria developed for the assessment of response to immunotherapy

Criteria, year [reference]	irRC, 2009 [17]	irRECIST, 2013 [33]	iRECIST, 2017 [34]	imRECIST, 2018 [35]
Baseline
Definition of target lesion	World Health Organization criteria +5 cutaneous targets	RECIST 1.1	RECIST 1.1	RECIST 1.1
Definition of non-target lesion	Not specified	RECIST 1.1	RECIST 1.1	RECIST 1.1
Definition of lymph node	Not specified	RECIST 1.1	RECIST 1.1	RECIST 1.1
Follow-up
New lesion	≥ 5 × 5 mm; up to 5/organ; 5 new cutaneous and 10 visceral lesions PD not defined Measurement of new lesions included in the total tumour burden	RECIST 1.1 PD not defined Measurement of new lesions included in the total tumour burden	RECIST 1.1 Defined unconfirmed PD	RECIST 1.1 PD not defined
Non-target lesion	Only to define irCR	Only to define irCR	RECIST 1.1 May define UPD	Only to define irCR
PD definition	Determined only on measurable disease (≥ 25% increase in the sum of target lesions and new lesions from the nadir) Negated by subsequent non-PD assessment ≥ 4 weeks	Determined only on measurable disease (≥ 20% increase in the sum of target lesions and new lesions from the nadir) Negated by subsequent non-PD assessment ≥ 4 weeks	Confirmed PD if : - Unconfirmed PD of target lesions on previous exam and increase in tumour burden of target lesions ≥ 5 mm - Unconfirmed PD of non-target lesions and their significant increase - Unconfirmed PD for new lesions and increase in tumour burden ≥ 5 mm or increase in the number of new lesion	Determined only on measurable disease (≥ 20% increase in the sum of target lesion and new lesions from the nadir) The presence of new lesions does not define PD Negated by subsequent non-PD assessment ≥ 4 weeks

irRC Immune-related response criteria, imRECIST Immune-modified RECIST, PD Progressive disease